Tiziana expands Phase 2 MS trial to fifth site, commences patient dosing
Published: 10:59 13 Jun 2025 EDT
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has initiated patient dosing at the Weill Cornell Medicine Multiple Sclerosis Center in New York City as part of its ongoing Phase 2 clinical trial of intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS).
Weill Cornell marks the fifth site participating in the trial, joining Yale University, Johns Hopkins University, Brigham and Women’s Hospital, and the University of Massachusetts.
Tiziana highlighted that the addition of this site further expands the reach and capacity of the study, which is focused on evaluating the safety and efficacy of foralumab in treating multiple sclerosis, a chronic autoimmune disorder of the central nervous system.
“The addition of this esteemed site further strengthens our Phase 2 clinical trial, which aims to address the significant unmet medical need in MS treatment,” Tiziana Life Sciences CEO Ivor Elrifi said.
“We look forward to collaborating closely with the team at Weill Cornell and our other esteemed clinical partners as we progress toward potentially transformative outcomes for patients.”
Upon completion of the blinded portion of the trial, all participants, including those who received placebo, will have the option to continue in a six-month open-label extension phase.
This extension will allow researchers to assess long-term safety and potential sustained benefits of foralumab in the target patient group.
Shares of Tiziana moved higher on the update, adding 11% at about $1.60 on Friday morning.
